Lipocine Common Stock Total Equity from 2010 to 2025

LPCN Stock  USD 3.07  0.09  2.85%   
Lipocine Common Stock Total Equity yearly trend continues to be very stable with very little volatility. Common Stock Total Equity is likely to grow to about 10.7 K this year. Common Stock Total Equity is the total value of common stock equity held by shareholders, representing their ownership interest in the company. View All Fundamentals
 
Common Stock Total Equity  
First Reported
2012-03-31
Previous Quarter
8.8 K
Current Value
8.9 K
Quarterly Volatility
2.6 K
 
Yuan Drop
 
Covid
Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Other Operating Expenses of 14.9 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 0.68 or Book Value Per Share of 4.22. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Latest Lipocine's Common Stock Total Equity Growth Pattern

Below is the plot of the Common Stock Total Equity of Lipocine over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. Lipocine's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipocine's overall financial position and show how it may be relating to other accounts over time.
Common Stock Total Equity10 Years Trend
Slightly volatile
   Common Stock Total Equity   
       Timeline  

Lipocine Common Stock Total Equity Regression Statistics

Arithmetic Mean4,347
Geometric Mean2,439
Coefficient Of Variation90.32
Mean Deviation3,529
Median2,174
Standard Deviation3,926
Sample Variance15.4M
Range10.4K
R-Value0.94
Mean Square Error1.8M
R-Squared0.89
Slope778.60
Total Sum of Squares231.2M

Lipocine Common Stock Total Equity History

202510.7 K
202410.2 K
2021 8830.0
2020 7005.0
2019 3766.0
2018 2174.0
2017 2127.0

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as Common Stock Total Equity, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Common Stock Total Equity10.2 K10.7 K
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.75)
Revenue Per Share
1.486
Quarterly Revenue Growth
137.519
Return On Assets
(0.15)
Return On Equity
(0.20)
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.